Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Non-Current Assets (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Other Non-Current Assets for 4 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 21.57% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 21.57% year-over-year, with the annual reading at $1.2 million for FY2025, 21.57% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $1.2 million at Orchestra BioMed Holdings, down from $1.3 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $4.7 million in Q4 2022, with the low at $421000.0 in Q1 2023.
  • Average Other Non-Current Assets over 4 years is $1.2 million, with a median of $1.0 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets tumbled 83.68% in 2023, then soared 115.73% in 2024.
  • Over 4 years, Other Non-Current Assets stood at $4.7 million in 2022, then crashed by 83.68% to $769000.0 in 2023, then surged by 32.64% to $1.0 million in 2024, then increased by 21.57% to $1.2 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.2 million, $1.3 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.